Turning the TIDE: oligonucleotide development trends
European Pharmaceutical Review
APRIL 14, 2023
Oligonucleotide therapeutics represent a relatively novel class of drug, with the potential to modulate drug targets that were previously considered intractable, and with the benefit of fast clinical development times. Small interfering RNA (siRNA) were one of the most preferred drug delivery methods. The answers?
Let's personalize your content